News & Updates

First-line treatment with tumour necrosis factor-α (TNF-α) blockers is both safe and effective in children with inflammatory bowel disease (IBD), according to a recent study. Early drug initiation even cuts the likelihood of treatment failure and leads to fewer extraintestinal symptoms.

Adhering to a healthy lifestyle may be a means to counteract the genetic risk of lethal prostate cancer, a study finds.

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are superior to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in reducing renal outcomes among patients with type 2 diabetes (T2D) in Hong Kong, a real-world population-based study by the University of Hong Kong has shown.

The neurokinin-3 receptor antagonist fezolinetant reduced the frequency and severity of menopause-associated vasomotor symptoms (VMS), according to results of the extension arm of the phase III Skylight 2 trial presented at ENDO 2022.

Infants born to mothers who popped vitamin D during pregnancy are less likely to develop atopic eczema compared with their counterparts whose mothers received placebo, as shown in the UK Maternal Vitamin D Osteoporosis Study (MAVIDOS).

Coinfection with hepatitis B virus (HBV) among patients with tuberculosis (TB) appears to be 38-percent to 450-percent more prevalent than published estimates from the Polaris group of region-specific overall HBV prevalence, suggest the results of a meta-analysis.